Who
Darin Lippoldt
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Neurocrine Biosciences; EVP, General Counsel, Volcano.
In numbers
- Trades disclosed
- 294
- Buys
- 0
- Sells
- 77
- Bought
- $0
- Sold
- $40.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Feb 2011
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —4,483 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $378K2,419 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —4,483 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $378K2,419 at $156.22 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $815K10,000 at $81.49 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.8M10,000 at $179.60 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $815K10,000 at $81.49 | filing |
| 9 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.8M10,000 at $179.60 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $661K8,110 at $81.49 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,110 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,690 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.4M8,110 at $170.03 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $138K1,690 at $81.49 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $289K1,690 at $170.81 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,110 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,690 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $661K8,110 at $81.49 | filing |
| 29 Jun 2026filed 30 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.4M8,110 at $170.03 | filing |
News
Where Will Neurocrine Biosciences Be in 5 Years?NBIX · fool.com · 25 Oct 2026Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromeNBIX · prnewswire.com · 22 Oct 2026Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaNBIX · prnewswire.com · 16 Oct 2026
0 headlines in the last 90 days name Darin Lippoldt; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.